Literature DB >> 20974020

Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae.

S-H Lin1, C-C Lai, C-K Tan, W-H Liao, P-R Hsueh.   

Abstract

In contrast to bacteraemic pneumococcal community-acquired pneumonia (CAP), there is a paucity of data on the clinical characteristics and outcomes of non-bacteraemic pneumococcal CAP. This retrospective study compared the outcome of hospitalized patients with bacteraemic and non-bacteraemic pneumococcal CAP treated at a medical centre from 2004 to 2008. Data on clinical outcomes including all-cause mortality, length of hospital stay, need for intensive-care unit admission and extrapulmonary involvement were analysed. In all, 221 patients with pneumococcal pneumonia (87 bacteraemic, 134 non-bacteraemic) were included. Patients with bacteraemic pneumococcal pneumonia (BPP) were older than those with non-BPP (46·2 ± 30·7 years vs. 21·7 ± 30·8 years, P<0·001) and were more likely to have underlying medical diseases (66·7% vs. 33·6%, P<0·001). The overall mortality rates at 7, 14, and 30 days were significantly higher in BPP than non-BPP patients (12·6% vs. 2·2%, 14·9% vs. 3·7%, 19·5% vs. 5·1%, all P<0·01). Multivariate logistic regression analysis showed that pneumococcal bacteraemia was correlated with extrapulmonary involvement (odds ratio 5·46, 95% confidence interval 1·97-15·16, P=0·001). In conclusion, S. pneumoniae bacteraemia increased the risk of mortality and extrapulmonary involvement in patients with pneumococcal CAP.

Entities:  

Mesh:

Year:  2010        PMID: 20974020     DOI: 10.1017/S0950268810002402

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  13 in total

1.  Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.

Authors:  J M Bordon; R Fernandez-Botran; T L Wiemken; P Peyrani; S M Uriarte; F W Arnold; L Rodriquez-Hernandez; M J Rane; R R Kelley; L E Binford; S Uppatla; R Cavallazzi; F Blasi; S Aliberti; M I Restrepo; S Fazeli; A Mathur; M Rahmani; K Ayesu; J Ramirez
Journal:  Infection       Date:  2015-09-30       Impact factor: 3.553

2.  30-day mortality in UK patients with bacteraemic community-acquired pneumonia.

Authors:  M Melzer; C Welch
Journal:  Infection       Date:  2013-05-24       Impact factor: 3.553

3.  Neutrophils Are Required During Immunization With the Pneumococcal Conjugate Vaccine for Protective Antibody Responses and Host Defense Against Infection.

Authors:  Essi Y I Tchalla; Manmeet Bhalla; Elizabeth A Wohlfert; Elsa N Bou Ghanem
Journal:  J Infect Dis       Date:  2020-09-14       Impact factor: 5.226

4.  Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared.

Authors:  S P van Mens; A M M van Deursen; S C de Greeff; H E de Melker; L M Schouls; A van der Ende; M J M Bonten; E A M Sanders; B J M Vlaminckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-01       Impact factor: 3.267

5.  A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?

Authors:  Cristina Vazquez Guillamet; Rodrigo Vazquez; Jonas Noe; Scott T Micek; Marin H Kollef
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 6.  Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.

Authors:  Gwan-Han Shen; Thomas Chang-Yao Tsao; Shang-Jyh Kao; Jen-Jyh Lee; Yen-Hsu Chen; Wei-Chung Hsieh; Gwo-Jong Hsu; Yen-Tao Hsu; Ching-Tai Huang; Yeu-Jun Lau; Shih-Ming Tsao; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2012-01-28       Impact factor: 5.283

7.  The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.

Authors:  Charles Feldman; Sipho K Dlamini; Shabir A Madhi; Susan Meiring; Anne von Gottberg; Janetta C de Beer; Margreet de Necker; Marthinus P Stander
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

8.  Impact of positive chest X-ray findings and blood cultures on adverse outcomes following hospitalized pneumococcal lower respiratory tract infection: a population-based cohort study.

Authors:  Marlene Skovgaard; Henrik C Schønheyder; Thomas Benfield; Rikke B Nielsen; Jenny D Knudsen; Jette Bangsborg; Christian Østergaard; Hans-Christian Slotved; Helle Bossen Konradsen; Lotte Lambertsen; Reimar W Thomsen
Journal:  BMC Infect Dis       Date:  2013-05-02       Impact factor: 3.090

9.  Pneumococcal pneumonia: differences according to blood culture results.

Authors:  Alberto Capelastegui; Rafael Zalacain; Amaia Bilbao; Mikel Egurrola; Luis Alberto Ruiz Iturriaga; Jose M Quintana; Ainhoa Gomez; Cristobal Esteban; Pedro P España
Journal:  BMC Pulm Med       Date:  2014-08-05       Impact factor: 3.317

10.  Comparison of the frequency of bacterial and viral infections among children with community-acquired pneumonia hospitalized across distinct severity categories: a prospective cross-sectional study.

Authors:  Amanda C Nascimento-Carvalho; Olli Ruuskanen; Cristiana M Nascimento-Carvalho
Journal:  BMC Pediatr       Date:  2016-07-22       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.